| Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) (NCT05356195) | Vertex Pharmaceuticals Incorporated | 2022-05-03 |
| Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) (NCT05329649) | Vertex Pharmaceuticals Incorporated | 2022-05-02 |
| EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) (NCT05444894) | Editas Medicine, Inc. | 2022-04-29 |
| Long Term Beta Thalassemia Treatment: Findings From The Extension Period (NCT06490601) | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 2022-04-01 |
| A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) (NCT04853576) | Editas Medicine, Inc. | 2021-05-04 |
| Transcranial Doppler in Children With Hemoglobinopathies (NCT04798157) | Sohag University | 2021-04-01 |
| A Long-term Follow-up Study in Participants Who Received CTX001 (NCT04208529) | Vertex Pharmaceuticals Incorporated | 2021-01-20 |
| Prevalence and Hematological Characteristics of Hemoglobinopathies (NCT07180836) | Bacha Khan Medical College | 2021-01-15 |
| Prevalence of Abnormal Haemoglobin Variants in Metropolitan Chattogram, Bangladesh (NCT07305181) | Bangladesh Bioscience Research Group | 2021-01-01 |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (NCT04644016) | Memorial Sloan Kettering Cancer Center | 2020-11-20 |
| Pediatrics HOT COVID-19 Database in NY Tristate (NCT04445402) | Columbia University | 2020-04-30 |
| ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19 (NCT06831799) | Hospital Universitari Vall d'Hebron Research Institute | 2020-04-15 |
| Screening for Hemoglobinopathies in Pregnant Women (NCT04029142) | University Hospital, Basel, Switzerland | 2019-07-03 |
| A Blood Stem Cell Transplant for Sickle Cell Disease (NCT03249831) | City of Hope Medical Center | 2019-01-04 |
| A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease (NCT03745287) | Vertex Pharmaceuticals Incorporated | 2018-11-27 |
| A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia (NCT03655678) | Vertex Pharmaceuticals Incorporated | 2018-09-14 |
| In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) (NCT02986698) | University of California, San Francisco | 2017-10-05 |
| Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group (NCT03141398) | Hamad Medical Corporation | 2017-08-01 |
| Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients (NCT03609840) | University of California, San Francisco | 2017-05-24 |
| Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders (NCT03128996) | Washington University School of Medicine | 2017-03-20 |
| Hemoglobinopathy Nursing Program and Pediatric Nursing Students (NCT05389891) | Beni-Suef University | 2017-02-27 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study (NCT03733249) | Bellicum Pharmaceuticals | 2017-01-01 |
| Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT) (NCT03609814) | University of California, San Francisco | 2016-01-26 |
| Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients (NCT03609827) | University of California, San Francisco | 2015-09-01 |
| Hepatitis C Virus Infection in Patients With Hemoglobinopathies (NCT03149289) | Società Italiana Talassemie ed Emoglobinopatie | 2015-03-01 |
| Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases (NCT02231710) | Bellicum Pharmaceuticals | 2015-02-01 |
| Non-Myeloablative Conditioning and Bone Marrow Transplantation (NCT01850108) | Vanderbilt-Ingram Cancer Center | 2013-05-01 |
| CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation (NCT01966367) | Diane George | 2013-03-01 |
| Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC) (NCT01666080) | Masonic Cancer Center, University of Minnesota | 2012-08-01 |
| Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (NCT01316549) | University of California, San Francisco | 2011-01-01 |
| Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies (NCT00887081) | Azienda Ospedaliera V. Cervello | 2009-01-01 |
| Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders (NCT00744692) | Duke University | 2008-10-01 |
| Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders (NCT01050855) | Children's Hospital of Philadelphia | 2008-01-01 |
| Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload (NCT00673608) | Novartis | 2007-11-01 |
| Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes (NCT00102245) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2005-01-18 |
| Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies (NCT00153985) | Dana-Farber Cancer Institute | 2004-03-01 |
| A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen (NCT00427661) | University of Pittsburgh | 2002-06-01 |
| Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia (NCT00034528) | National Institute of Allergy and Infectious Diseases (NIAID) | 2001-09-01 |
| Stroke Prevention in Sickle Cell Anemia (STOP 1) (NCT00000592) | Augusta University | 1994-07-01 |
| Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG) (NCT00000602) | National Heart, Lung, and Blood Institute (NHLBI) | 1994-04-01 |
| Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) (NCT00000586) | National Heart, Lung, and Blood Institute (NHLBI) | 1992-01-01 |
| Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone (NCT00000588) | Case Western Reserve University | 1989-06-05 |
| Penicillin Prophylaxis in Sickle Cell Disease (PROPS) (NCT00000585) | National Heart, Lung, and Blood Institute (NHLBI) | 1983-08-01 |
| Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis (NCT00000595) | National Heart, Lung, and Blood Institute (NHLBI) | 1978-01-01 |